{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:57:12Z","timestamp":1772009832626,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04646-2","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:25:57Z","timestamp":1761204357000},"page":"4547-4554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for cabazitaxel"],"prefix":"10.1007","volume":"399","author":[{"given":"Min","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changjing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"10","key":"4646_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/14740338.2022.2131770","volume":"21","author":"D Arku","year":"2022","unstructured":"Arku D, Yousef C, Abraham I (2022) Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning. Expert Opin Drug Saf 21(10):1235\u20131238. https:\/\/doi.org\/10.1080\/14740338.2022.2131770","journal-title":"Expert Opin Drug Saf"},{"key":"4646_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.urology.2024.04.035","volume":"191","author":"E Bologna","year":"2024","unstructured":"Bologna E, Licari LC, Franco A et al (2024) Incidence and management of radiation cystitis after pelvic radiotherapy for prostate cancer: analysis from a national database. Urology 191:86\u201392. https:\/\/doi.org\/10.1016\/j.urology.2024.04.035","journal-title":"Urology"},{"key":"4646_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/spcare-2024-004937","author":"A Dosanjh","year":"2024","unstructured":"Dosanjh A, Coupland B, Mytton J et al (2024) High early mortality following percutaneous nephrostomy in metastatic cancer: a national analysis of outcomes. BMJ Support Palliat Care. https:\/\/doi.org\/10.1136\/spcare-2024-004937","journal-title":"BMJ Support Palliat Care"},{"issue":"3","key":"4646_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/MCP.0000000000000156","volume":"21","author":"SE Evans","year":"2015","unstructured":"Evans SE, Ost DE (2015) Pneumonia in the neutropenic cancer patient. Curr Opin Pulm Med 21(3):260\u2013271. https:\/\/doi.org\/10.1097\/MCP.0000000000000156","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"4646_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40266-013-0078-8","volume":"30","author":"GM Keating","year":"2013","unstructured":"Keating GM (2013) Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer. Drugs Aging 30(5):359\u2013365. https:\/\/doi.org\/10.1007\/s40266-013-0078-8","journal-title":"Drugs Aging"},{"issue":"5","key":"4646_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10147-024-02501-7","volume":"29","author":"S Kimura","year":"2024","unstructured":"Kimura S, Shigeta K, Tamura S et al (2024) Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022. Int J Clin Oncol 29(5):559\u2013563. https:\/\/doi.org\/10.1007\/s10147-024-02501-7","journal-title":"Int J Clin Oncol"},{"key":"4646_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31893","author":"A Lashansky","year":"2025","unstructured":"Lashansky A, Grishin E, Budnik I et al (2025) Pediatric extreme thrombocytosis: etiology, management, and outcomes. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.31893","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"4646_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/bju.16558","volume":"135","author":"A Lazarovich","year":"2025","unstructured":"Lazarovich A, Kristof TW, Steadman S et al (2025) Prostate cancer and solid organ transplantation: patient management and outcomes. BJU Int 135(2):339\u2013345. https:\/\/doi.org\/10.1111\/bju.16558","journal-title":"BJU Int"},{"issue":"1","key":"4646_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-017-0119-3","volume":"17","author":"GN Malalagama","year":"2017","unstructured":"Malalagama GN, Chryssidis S, Parnis FX (2017) CT findings in patients with cabazitaxel-induced pelvic pain and haematuria: a case series. Cancer Imaging 17(1):17. https:\/\/doi.org\/10.1186\/s40644-017-0119-3","journal-title":"Cancer Imaging"},{"issue":"41","key":"4646_CR10","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.18632\/oncotarget.27031","volume":"10","author":"Z Malik","year":"2019","unstructured":"Malik Z, Heidenreich A, Bracarda S et al (2019) Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme. Oncotarget 10(41):4161\u20134168. https:\/\/doi.org\/10.18632\/oncotarget.27031","journal-title":"Oncotarget"},{"issue":"7","key":"4646_CR11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jgo.2020.02.014","volume":"11","author":"N Matsubara","year":"2020","unstructured":"Matsubara N, Suzuki K, Kazama H et al (2020) Cabazitaxel in patients aged \u226580 years with castration-resistant prostate cancer: results of a post-marketing surveillance study in Japan. J Geriatr Oncol 11(7):1067\u20131073. https:\/\/doi.org\/10.1016\/j.jgo.2020.02.014","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"4646_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07131-6","volume":"20","author":"H Matsuyama","year":"2020","unstructured":"Matsuyama H, Matsubara N, Kazama H et al (2020) Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg\/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study. BMC Cancer 20(1):649. https:\/\/doi.org\/10.1186\/s12885-020-07131-6","journal-title":"BMC Cancer"},{"issue":"10","key":"4646_CR13","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1158\/1078-0432.CCR-22-3360","volume":"29","author":"A Omlin","year":"2023","unstructured":"Omlin A, Cathomas R, von Amsberg G et al (2023) Randomized phase II cabazitaxel dose individualization and neutropenia prevention trial in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 29(10):1887\u20131893. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3360","journal-title":"Clin Cancer Res"},{"issue":"28","key":"4646_CR14","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","volume":"35","author":"S Oudard","year":"2017","unstructured":"Oudard S, Fizazi K, Sengel\u00f8v L et al (2017) Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol 35(28):3189\u20133197. https:\/\/doi.org\/10.1200\/JCO.2016.72.1068","journal-title":"J Clin Oncol"},{"issue":"12","key":"4646_CR15","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jamaoncol.2023.4255","volume":"9","author":"S Oudard","year":"2023","unstructured":"Oudard S, Ratta R, Voog E et al (2023) Biweekly vs triweekly cabazitaxel in older patients with metastatic castration-resistant prostate cancer: the CABASTY phase 3 randomized clinical trial. JAMA Oncol 9(12):1629\u20131638. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4255","journal-title":"JAMA Oncol"},{"issue":"6","key":"4646_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/ajco.12679","volume":"13","author":"P Parente","year":"2017","unstructured":"Parente P, Ng S, Parnis F et al (2017) Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program. Asia Pac J Clin Oncol 13(6):391\u2013399. https:\/\/doi.org\/10.1111\/ajco.12679","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"4646_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2217\/fon-2020-0672","volume":"17","author":"C Pobel","year":"2021","unstructured":"Pobel C, Auclin E, Procureur A et al (2021) Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review. Future Oncol 17(1):91\u2013102. https:\/\/doi.org\/10.2217\/fon-2020-0672","journal-title":"Future Oncol"},{"issue":"3","key":"4646_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4103\/tcmj.tcmj_163_21","volume":"34","author":"A Purkayastha","year":"2021","unstructured":"Purkayastha A, Sharma N, Taneja S et al (2021) Sociodemographic, clinical profile, and treatment characteristics of oncology patients developing radiation recall phenomenon: two tertiary care center\u2019s experience of an eternal unpredictable phenomenon of cancer treatment. Tzu Chi Med J 34(3):337\u2013347. https:\/\/doi.org\/10.4103\/tcmj.tcmj_163_21","journal-title":"Tzu Chi Med J"},{"issue":"2","key":"4646_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63\u201389. https:\/\/doi.org\/10.14740\/wjon1191","journal-title":"World J Oncol"},{"issue":"3","key":"4646_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1001\/jamaophthalmol.2019.5961","volume":"138","author":"MJ Simcoe","year":"2020","unstructured":"Simcoe MJ, Weisschuh N, Wissinger B, Hysi PG, Hammond CJ (2020) Genetic heritability of pigmentary glaucoma and associations with other eye phenotypes. JAMA Ophthalmol 138(3):294\u2013299. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.5961","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"4646_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1854","volume":"15","author":"B Sun","year":"2023","unstructured":"Sun B, Lovell JF, Zhang Y (2023) Current development of cabazitaxel drug delivery systems. Wires Nanomed Nanobiotechnol 15(2):e1854. https:\/\/doi.org\/10.1002\/wnan.1854","journal-title":"Wires Nanomed Nanobiotechnol"},{"issue":"12","key":"4646_CR22","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/jjco\/hyz108","volume":"49","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Matsubara N, Kazama H et al (2019) Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study. Jpn J Clin Oncol 49(12):1157\u20131163. https:\/\/doi.org\/10.1093\/jjco\/hyz108","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"4646_CR23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2165\/11591390-000000000-00000","volume":"71","author":"C Villanueva","year":"2011","unstructured":"Villanueva C, Bazan F, Kim S et al (2011) Cabazitaxel: a novel microtubule inhibitor. Drugs 71(10):1251\u20131258. https:\/\/doi.org\/10.2165\/11591390-000000000-00000","journal-title":"Drugs"},{"key":"4646_CR24","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2147\/DDDT.S64940","volume":"8","author":"P Vrignaud","year":"2014","unstructured":"Vrignaud P, Semiond D, Benning V et al (2014) Preclinical profile of cabazitaxel. Drug des Devel Ther 8:1851\u20131867. https:\/\/doi.org\/10.2147\/DDDT.S64940","journal-title":"Drug des Devel Ther"},{"issue":"2","key":"4646_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccm.2016.12.005","volume":"38","author":"JL Wong","year":"2017","unstructured":"Wong JL, Evans SE (2017) Bacterial pneumonia in patients with cancer: novel risk factors and management. Clin Chest Med 38(2):263\u2013277. https:\/\/doi.org\/10.1016\/j.ccm.2016.12.005","journal-title":"Clin Chest Med"},{"issue":"1","key":"4646_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5942-4","volume":"19","author":"Y Yanai","year":"2019","unstructured":"Yanai Y, Kosaka T, Hongo H et al (2019) Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report. BMC Cancer 19(1):720. https:\/\/doi.org\/10.1186\/s12885-019-5942-4","journal-title":"BMC Cancer"},{"issue":"1","key":"4646_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40644-025-00872-2","volume":"25","author":"AH Zedan","year":"2025","unstructured":"Zedan AH, Gade JS, Zieger KEA et al (2025) Cabazitaxel-induced ureteritis in metastatic castration-resistant prostate cancer patients: a single center case series 2014\u20132024. Cancer Imaging 25(1):54. https:\/\/doi.org\/10.1186\/s40644-025-00872-2","journal-title":"Cancer Imaging"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04646-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04646-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04646-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:00:13Z","timestamp":1772006413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04646-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4646"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04646-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"24 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since all data were obtained from a publicly available database, no ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}